Product News - AlphaCor

AlphaCor uptake continues to increase with steady accreditation of US surgeons throughout this year. Outcome trends continue to be very positive, with falling incidences of the complications recognized during earlier trials. Current to end June 2004, 152 AlphaCor devices have been implanted, with mean follow-up of 11.8 months (1-68 months), in eyes with 0-11 prior failed grafts (mean 2.14).

The AlphaCor Scientific Advisory Board met during ASCRS and emphasized the importance of patient selection and following clinical trial guidance in minimizing post-operative complication rates. As a reminder, AlphaCor is not approved for use in children, dry eyes, or herpetic patients. Contact us for an updated list of peer-reviewed publications and search the internet for non-peer-reviewed postings of others’ outcomes.

AlphaCor User feedback

Several surgeons internationally requested screening of the topical medications they use with AlphaCor. Results of screening tests are available through www.argusconnect.com. It was also suggested that we provide ‘reminder stickers’ for patient charts regarding medications likely to cause optic opacification. These stickers are now available from your Clinical Account Manager. Data collection through ArgusConnect remains very strong, with most surgeons keeping their data current. Analysis allows early identification of risk/protective factors such as for stromal melts, optic deposits and retroprosthetic membranes and the Scientific Advisory Board will conduct its first formal review for peer-reviewed publication later this year.

Example of Caution Sticker Available

<table>
<thead>
<tr>
<th>CAUTION: POST STAGE II ALPHA COR SURGERY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alphagan®, Betagan®, and some topical tetracyclines may stain the device.</td>
</tr>
<tr>
<td>Co-administration of topical beta-blockers with topical steroids may precipitate calcification</td>
</tr>
<tr>
<td>More Details: See Surgeons’ Manual or <a href="http://www.coopervisionsurgical.com">www.coopervisionsurgical.com</a></td>
</tr>
</tbody>
</table>

ArgusConnect feedback

In the upcoming months, ArgusConnect will be re-launched as CVSSConnect. The new and improved system will incorporate many improvements users have asked for to facilitate data entry, patient management and device ordering. Updates will be made available from your Clinical Account Manager.

Accreditation

The next formal AlphaCor accreditation course will be held on Thursday 21st October 2004 in New Orleans, just before AAO. Any accredited surgeon who would like a ‘refresher’ or to try the newer techniques and instruments is welcome to attend. Please email your local Clinical Account Manager or info@coopervisionsurgical.com

Meeting News

ASCRS update

CooperVision Surgical exhibited at ASCRS, San Diego, and we thank all those who met with us. Our third AlphaCor Users’ Meeting was held and featured feedback from Edward Holland, David Hardten and Steven Hamilton, as well as an overview of current outcome data and a summary of evolving surgical techniques.

Forthcoming meetings

CooperVision Surgical will hold a Users’ Meeting during ESCRIS, Paris, September 2004, which will be breakfast on Sunday 19th September. Those wishing to register attendance please e-mail justinstillitano@coopervisionsurgical.com.

CooperVision Surgical will exhibit and hold a Users’ meeting during AAO, New Orleans; the Users’ meeting will be a breakfast event on Sunday 24th October.

Company News and Customer Support

We’re pleased to announce the promotion of Ms Beth Spearman to Senior Clinical Account Manager, in recognition of her broadened role in assisting the other account managers and taking on special projects for the company.

Look out for the new CooperVision Surgical branding on all packaging and labeling and for the new company website, currently under construction.

www.coopervisionsurgical.com
email:info@coopervisionsurgical.com